Advances and Challenges in the Investigation of Metastasis in Diffuse Large B-Cell Lymphoma-Reference-Cited by-同舟云学术

Advances and Challenges in the Investigation of Metastasis in Diffuse Large B-Cell Lymphoma

Published:2022-12 Issue:22 Volume:22 Page:2808-2812
ISSN:1389-5575
Container-title:Mini-Reviews in Medicinal Chemistry
language:en
Short-container-title:MRMC

Author:

Chen Yingying¹,Yang Mingzhen¹,Xia Leiming¹²,Jiang Lingling¹,Liu Lixia¹,Ruan Min³,Zhou Zhicheng⁴

Affiliation:

1. Department of Hematology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, China

2. Anhui Provincial Institute of Translational Medicine, Hefei, China

3. Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

4. Department of Emergency, The Third Affiliated Hospital of Anhui Medical University, Hefei, China

Abstract

Abstract: Diffuse large B-cell lymphoma (DLBCL), an aggressive cancer of the B cells, is the most common pathological type of non-Hodgkin’s lymphoma (NHL), and the typical heterogeneity of the disease is due to metastasis, which indicates a poor prognosis. Currently, the key mechanism of metastasis remains largely unknown, and research is focusing on the same in DLBCL. Recent studies have focused on the role of mesenchymal-epithelial transition (MET) and epithelial-mesenchymal transition (EMT), the extracellular matrix (ECM), chemokines, cancer stem cells, and non-coding RNAs in DLBCL. Here, we have summarised the advances and challenges in the investigation of metastasis in DLBCL and attempted to reveal the potential targets that can improve patient survival.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology,General Medicine

Reference53 articles.

1. Youssef Y.; Karkhanis V.; Chan W.K.; Jeney F.; Canella A.; Zhang X.; Sloan S.; Prouty A.; Helmig-Mason J.; Tsyba L.; Hanel W.; Zheng X.; Zhang P.; Chung J.H.; Lucas D.M.; Kauffman Z.; Larkin K.; Strohecker A.M.; Ozer H.G.; Lapalombella R.; Zhou H.; Xu-Monette Z.Y.; Young K.H.; Han R.; Nurmemmedov E.; Nuovo G.; Maddocks K.; Byrd J.C.; Baiocchi R.A.; Alinari L.; Transducin β-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma Haematologica 2021,106(11),2927-2939

2. Hui D.; Proctor B.; Donaldson J.; Shenkier T.; Hoskins P.; Klasa R.; Savage K.; Chhanabhai M.; Gascoyne R.D.; Connors J.M.; Sehn L.H.; Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma 2010,51(9),1658-1667

3. Shen R.; Xu P.P.; Wang N.; Yi H.M.; Dong L.; Fu D.; Huang J.Y.; Huang H.Y.; Janin A.; Cheng S.; Wang L.; Zhao W.L.; Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma. Clin Transl Med 2020,10(7),e221

4. Adams H.J.; de Klerk J.M.; Fijnheer R.; Heggelman B.G.; Dubois S.V.; Nievelstein R.A.; Kwee T.C.; Where does diffuse large B-cell lymphoma relapse? J Comput Assist Tomogr 2016,40(4),531-536

5. Zhang M.; Du Y.; Shang J.; Zhang D.; Dong X.; Chen H.; Knockdown of UCA1 restrains cell proliferation and metastasis of diffuse large B-cell lymphoma by counteracting miR-331-3p expression Oncol Lett 2021,21(1),39